Tariq Shafi MD MHS
Acute Renal Failure, Chronic Renal Failure & Dialysis, Hypertension
Director, Division of Nephrology, Baylor Scott and White Health, Temple, TX
Join to View Full Profile
2601 Thornton LnTemple, TX 76502
Phone+1 254-724-6622
Fax+1 254-724-6620
Dr. Shafi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins Bloomberg School of Public HealthMHS, Clinical Epidemiology, 2006 - 2008
Johns Hopkins UniversityFellowship, Nephrology, 2005 - 2008
Wayne State University School of MedicineResidency, Internal Medicine, 1993 - 1996
Dow University of Health SciencesClass of 1990
Certifications & Licensure
TX State Medical License 2022 - 2027
MS State Medical License 2019 - 2023
MD State Medical License 2006 - 2019
MI State Medical License 1995 - 2011
IL State Medical License 2000 - 2002
American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Fellow (ASN) American Society of Nephrology
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Publications & Presentations
PubMed
- Mechanisms, Magnitude, and Consequence of Acute Estimated Glomerular Filtration Rate Change With Guideline-Directed Medical Therapy Initiation in Heart Failure.Tariq Shafi, Shane A Bobart
The American Journal of Cardiology. 2026-08-01 - Steroidal versus Nonsteroidal Mineralocorticoid Receptor Antagonists in CKD.Muhammad Shahzeb Khan, Ahmed Mustafa Rashid, Jennifer E Flythe, Laura M Dember, Tariq Shafi
Journal of the American Society of Nephrology. 2026-06-01 - Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY.Robert Weingold, Gerasimos Filippatos, Stefan D Anker, Christoph Wanner, Tariq Shafi
Journal of Diabetes and Its Complications. 2026-04-01
Press Mentions
Baylor Scott & White Research Institute to Lead National Study on Advanced Chronic Kidney Disease TreatmentApril 28th, 2026- The Changing Treatment Paradigm for IgANMay 12th, 2023
- Study Alerts Labs to Kidney Test DiscrepanciesJuly 6th, 2022
Grant Support
- Residual Kidney Function In ESRD: Measurements, Serum Markers And OutcomesNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
